1799Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study

1657Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study

468RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study Erik Dubberke, MD, MSPH; Robert Orenstein, DO; Paul Mariani, MD; Kathleen Mullane, DO, FIDSA; Mary Kay Sobcinski, RN, MHA; Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO; Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ; Infectious Disease, Sanford Health, Fargo, ND; University of Chicago...

Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection

BACKGROUND Fecal microbiota transplantation (FMT) has been shown to be safe and effective in treating refractory or relapsing C. difficile infection (CDI), but its use has been limited by practical barriers. We recently reported a small preliminary feasibility study using orally administered frozen fecal capsules. Following these early results, we now report our clinical experience in a large c...

Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut

BACKGROUND Fecal bacteriotherapy ('stool transplant') can be effective in treating recurrent Clostridium difficile infection, but concerns of donor infection transmission and patient acceptance limit its use. Here we describe the use of a stool substitute preparation, made from purified intestinal bacterial cultures derived from a single healthy donor, to treat recurrent C. difficile infection ...

In silico analysis of antibiotic-induced Clostridium difficile infection: Remediation techniques and biological adaptations

In this paper we study antibiotic-induced C. difficile infection (CDI), caused by the toxin-producing C. difficile (CD), and implement clinically-inspired simulated treatments in a computational framework that synthesizes a generalized Lotka-Volterra (gLV) model with SIR modeling techniques. The gLV model uses parameters derived from an experimental mouse model, in which the mice are administer...